Patient P-01360

Synthetic patientNBL-101 · Day 93 · 25–34 · M · baseline S14Open companion preview

Therapy response

Improving

Tolerance

Stable

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

78%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 47 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 59 GI-04 recommended — GI Support Protocol GI-04
Day 60 Patient accepted — Started GI-04 in the companion
Day 68 GI symptom burden −28% vs expected — GI Support Protocol GI-04
Day 74 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 47.

Primary contributors, last 14 days

Treatment adherence-9
GI instability+6
Toxicity+4
Inflammatory activity+3
Nutritional resilience-2

What helped?

GI Support Protocol GI-04Day 59
Result: symptom burden −28%

LIFE OS recommendation

Dietary Support Protocol NP-02

62%

probability of meaningful tolerance improvement

284 similar trajectories
66% showed improvement
median effect visible after 10 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 59 and rising
- WearableSleep 5.9 h, below personal baseline
Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 24/100
- Daily logFibre intake low in recent food logs
Drug metabolism and exposure ↑55
- DNADPYD *2A → slower clearance
- BloodToxicity index 48
Inflammatory signalling ↑45
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 59
Autonomic recovery ↓45
- WearableResting HR 73 bpm
- WearableShort sleep window

DNA

Fictional pharmacogenomic panel

DPYD *2A heterozygous
Slower drug clearance
CYP2D6 Normal metabolizer
Expected exposure
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 2 · butyrate capacity 24/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 48 ms
Sleep: 6.1 h
Steps: 6,542
Resting HR: 73 bpm

Daily log: GI score 59, nutritional resilience 40, adherence 47.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01465	55%	S14	NP-02	improved	56
P-01494	55%	S14	GI-04	improved	42
P-01433	53%	S14	GI-04	improved	48
P-01570	53%	S14	SC-12	improved	46
P-01339	52%	S14	GI-04	improved	54
P-01554	51%	S05	GI-04	improved	47
P-01539	50%	S14	GI-04	improved	43
P-01781	50%	S14	NP-02	improved	45
P-01786	50%	S07	ME-01	improved	46
P-01834	50%	S14	NP-02	improved	44
P-01447	49%	S15	GI-04	improved	44
P-01547	49%	S13	GI-04	improved	50